| Dall'Era, Maria |
| Recruiting | 2 | 74 | US | VIB4920, Placebo for VIB4920 | National Institute of Allergy and Infectious Diseases (NIAID) | Lupus Nephritis | 08/26 | 03/27 | | |
| Graf, Jonathan |
NAV3-33, NCT05246280: Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA |
|
|
| Terminated | 3 | 196 | US | TC99m-tilmanocept, tilmanocept, Lymphoseek | Navidea Biopharmaceuticals | Rheumatoid Arthritis | 07/24 | 07/24 | | |
| Active, not recruiting | 2 | 104 | NA | Placebo for VIB4920, VIB4920 with TNFi, VIB4920 without TNFi | National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN) | Rheumatoid Arthritis | 08/25 | 03/26 | | |
NCT06153095: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) |
|
|
| Recruiting | 1/2 | 30 | US, RoW | IMPT-514 | ImmPACT Bio | Systemic Lupus Erythematosus, Lupus Nephritis | 02/27 | 02/27 | | |
| Espino, Lidia |
| Recruiting | 2 | 200 | US | Pirfenidone, ESBRIET, matching placebo | Veterans Medical Research Foundation, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), San Diego Veterans Healthcare System, University of California, San Diego, University of California, San Francisco, Genentech, Inc. | Chronic Kidney Disease | 05/24 | 12/24 | | |
| Recruiting | 2 | 74 | US | VIB4920, Placebo for VIB4920 | National Institute of Allergy and Infectious Diseases (NIAID) | Lupus Nephritis | 08/26 | 03/27 | | |
| Jimarez, Diana |
| Recruiting | 2 | 74 | US | VIB4920, Placebo for VIB4920 | National Institute of Allergy and Infectious Diseases (NIAID) | Lupus Nephritis | 08/26 | 03/27 | | |
